#ACTRIMS26: Roche’s MS Drug Fenebrutinib Beats Ocrevus, Cutting Risk of Disability Progression by 12%

Why It Matters

Fenebrutinib offers an oral, BTK‑targeted alternative that could reshape PPMS treatment and diversify Roche’s revenue beyond its leading monoclonal antibody. Its efficacy and safety profile may accelerate adoption and pressure competitors to innovate.

Key Takeaways

• Fenebrutinib reduced disability progression risk by 12% versus Ocrevus
• Trial met primary endpoint of non‑inferiority in PPMS
• BTK inhibition offers oral alternative to infused therapies
• Safety profile comparable, with fewer infusion‑related reactions
• Success expands Roche’s pipeline beyond its flagship monoclonal

Pulse Analysis

Primary progressive multiple sclerosis remains one of the most challenging neurological disorders, with limited therapeutic options and a heavy reliance on infused biologics such as Ocrevus. Patients and clinicians have long sought an effective oral therapy that can halt disease progression without the logistical burdens of intravenous administration. The emergence of BTK inhibitors, which modulate B‑cell activity and microglial signaling, represents a promising avenue to address these unmet needs.

In the late‑stage ACTRIMS 26 trial, fenebrutinib demonstrated a 12% relative reduction in confirmed disability progression versus Ocrevus, while satisfying the non‑inferiority criteria set for PPMS. This oral agent not only matches the efficacy of the established monoclonal antibody but also offers a more convenient dosing regimen and a safety profile that reduces infusion‑related complications. The data underscore the therapeutic potential of targeting BTK pathways, positioning fenebrutinib as a credible challenger in a market dominated by injectable biologics.

Roche’s success with fenebrutinib could have far‑reaching implications for the company’s portfolio and the broader MS landscape. A positive regulatory outlook may unlock new revenue streams and reinforce Roche’s reputation for innovative neurology solutions. Competitors will likely accelerate their own BTK programs, while payers may reassess cost‑effectiveness models that previously favored Ocrevus. Ultimately, the trial’s outcome signals a shift toward more patient‑centric, oral treatment paradigms in progressive MS, potentially improving adherence and long‑term outcomes.